Strategies for Overcoming <em>KRAS</em> Mutations in Lung Cancer

Clinical Pearls

David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcomingKRASmutations in lung cancer. Gandara presented on this topic at the15th Annual International Lung Cancer Congress&reg;.

• KRASmutations tend to predict less response to chemotherapy or TKIs.
• It has been extremely difficult to develop drugs that directly inhibit KRAS.
• MEK inhibitors in combination with chemotherapy have shown downstream activity.
• SWOG 1408 will test this hypothesis with a MEK inhibitor (trametinib) in combination with chemotherapy (docetaxel) or an AKT inhibitor (GSK795).